![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Inex Innovate Gets CE-IVD Mark for Its OvaCis Rapid Cancer Test
Inex Innovate Gets CE-IVD Mark for Its OvaCis Rapid Cancer Test
Singapore-based Inex Innovate has received a CE-IVD mark for its OvaCis rapid test for detection of cancer in ovarian cysts.
The point-of-care test is used to rapidly differentiate between benign and malignant ovarian cysts in operating theaters.
The company released a previous version of the product in 2018. The latest version extends the product's shelf-life to a minimum of 18 months when stored at room temperature.
The company intends to launch the upgraded test in the EU and Southeast Asia in the fourth quarter of this year.
Upcoming Events
-
21Oct